Pfizer Begins Trial of Three-Dose COVID Vaccine for Babies and Toddlers

Pfizer said Friday that it is changing plans and testing three doses of the COVID-19 vaccine in infants and preschool children after two conventional shots were not strong enough for some children.

Pfizer announced the change after preliminary analysis showed that children aged 2 to 4 years did not have the expected strong immune response to the very low-dose shots the company is testing in the youngest children. .

It’s disappointing news for families worried about getting their kids vaccinated. Pfizer has tentative data on vaccine effectiveness in children under 5 years old at the end of the year, and it’s not clear how long the change will delay for a definitive answer.

Pfizer and partner BioNTech say that if the three-dose study is successful, they plan to apply for emergency authorization in the first half of 2022.

A children’s version of the Pfizer vaccine is already available for children 5 to 11 years old, a version that is one-third the dose given to others 12 years of age and older.


Video causes riot: California paramedics refuse to join dying man because of ‘some COVID laws’

For children under the age of 5, Pfizer is testing an even smaller dose, just 3 micrograms or a tenth of the adult dose.

The researchers analyzed a small group of young adults in the study a month after their second dose to see if they had developed the same levels of antibodies against the virus as teenagers and young adults. Vaccinated regularly or not.

Very low dose shots seem to be effective in children younger than 2 years of age, who produce similar levels of antibodies. But the immune response in 2- to 4-year-olds is lower than research claims, Pfizer vaccine research director Kathrin Jansen said Friday on a call with investors.

Instead of trying a higher-dose shot for preschoolers, Pfizer decided to expand the study to evaluate three of the very low-dose shots in all of the study participants – aged 6 months to 5 years. That third injection will be at least two shots. several months after the child’s second dose.

The companies said no safety concerns were detected in the study.

Jansen cites other data that shows booster shots given to people 16 years of age and older restore strong protection, a leap in immunity that scientists hope will also help fight the virus. new omicron bodies.

The companies are also preparing to test a booster shot for children ages 5 to 11 who have recently received two doses of the vaccine. And they are testing different dosage options for teen boosters.

If the additional pediatric trial is successful, “we’ll have a consistent three-dose approach for all ages,” Jansen said.



New research shows Moderna vaccine is significantly more likely to cause dangerous side effects

The Associated Press Health and Science Division receives support from the Howard Hughes Health Institute’s Science Education Department. AP is solely responsible for all content.

The Western Review did not review this Associated Press story prior to publication. As a result, it may contain editorial bias or may otherwise not meet our usual editorial standards. It is offered to our readers as a service from Western Magazine.

Western Magazine would like to quote comments for our articles! Due to Big Tech’s threat to unmonetize, we’ve temporarily removed the comments, but we’ve now implemented a solution to restore the chat Big Tech doesn’t want you to have. If you have any problems using the new commenting platform, please contact customer support at Welcome back! Pfizer Begins Trial of Three-Dose COVID Vaccine for Babies and Toddlers


USTimeToday is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button